Paul Hartmann AGSTU:PHH2 +0.49%64 ROE % is 7.89% as of Dec. 2025, which is 17% below its 10-year median of 9.45. GuruFocus rates STU:PHH2 with a GF Score™ of 64/100 and a GF Value™ of €229.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 58.85% on this metric.
The historical rank and industry rank for Paul Hartmann AG's ROE % or its related term are showing as below:
STU:PHH2'
s ROE % Range Over the Past 10 Years
Min: 2.65 Med: 9.45 Max: 11.72
Current: 5.32
During the past 13 years, Paul Hartmann AG's highest ROE % was 11.72%. The lowest was 2.65%. And the median was 9.45%.
STU:PHH2's ROE % is ranked better than 58.85% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs STU:PHH2: 5.32
Paul Hartmann AG (STU:PHH2) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Paul Hartmann AG ROE % Related Terms
Paul Hartmann AG ROE % Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's ROE % distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Paul Hartmann AG (STU:PHH2) has a ROE % of 7.89% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Paul Hartmann AG and its competitors. This is 17% below median its historical median of 9.45. Over the past decade, Paul Hartmann AG's ROE % has ranged from 2.65 to 11.72. According to the industry distribution chart, Paul Hartmann AG ranks #328 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 41.2%.
Is Paul Hartmann AG's ROE % too high?
Paul Hartmann AG's current ROE % of 7.89% is 17% below median its 10-year median of 9.45. Over the past 10 years, this metric has ranged from a low of 2.65 to a high of 11.72. The Medical Devices & Instruments industry median ROE % is 2.40. Paul Hartmann AG's value of 7.89% is 228.8% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #328 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #328 out of 797 companies for ROE %. This puts Paul Hartmann AG in the upper half of its industry. The industry median ROE % is 2.40. Paul Hartmann AG's value of 7.89% is 228.8% above this benchmark. Historically, Paul Hartmann AG's own ROE % has ranged from 2.65 to 11.72 over the past decade. While the company's 10-year median is 9.45 vs. the industry median of 2.40, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current ROE % of 7.89% is 228.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current ROE % is 7.89%, which is 17% below median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €229.60, compared to a current price of €205.00 — trading 10.7% below its estimated fair value. The current ROE % is 7.89%, which is 17% below median its 10-year median of 9.45 and 228.8% above the Medical Devices & Instruments industry median of 2.40. Paul Hartmann AG's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current ROE % is 7.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €205.00 is trading 10.7% below its estimated GF Value™ of €229.60.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for STU:PHH2:
ROE %: 7.89% (17% below median its 10-year median of 9.45)
GF Value™: €229.60 vs. price of €205.00 (10.7% below fair value)
Industry Position: 228.8% above the Medical Devices & Instruments median (#328 of 797)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
64GF Score
Get the complete analysis for STU:PHH2
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
